Active, Not RecruitingN/Aibogaine
Trifecta Research Study
Sponsored by Axial Therapeutic Research
NCT ID
NCT07717866
Target Enrollment
52 participants
Start Date
2022-08-01
Est. Completion
2026-11
About This Study
This observational study evaluates the impact of Ibogaine-Magnesium (IM), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), Magnetic e-Resonance Therapy (MeRT), and Physiological Supplementation (PS) on posttraumatic stress disorder (PTSD) and traumatic brain injury-related cognitive symptoms among Special Operations Forces (SOF) combat veterans.
Conditions Studied
Interventions
- •Magnetic e-Resonance Therapy (MeRT)
- •Ibogaine Hydrochloride with Magnesium Sulfate
- •5-methoxy-N,N-dimethyltryptamine
- •Physiological Supplementation
Eligibility
Age:18 Years - N/A
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria: * At least 18 years of age * Sponsored by SOC-F Program Exclusion Criteria (evaluated by SOC-F, not Axial Therapeutic Research): * Diagnosis of Schizophrenia, Bipolar I or II disorder for which patient has been hospitalized or medicated, Depersonalization and/or Derealization Disorder * Cerebellar dysfunction, Epilepsy, Psychosis or acute confusional state, Dementia * Prolonged corrected QT interval (QTc) Interval (450ms in males; 470ms in females) * History of heart failure or hypertrophic heart * Active blood clots (e.g., Pulmonary embolism, Deep vein thrombosis) * Major respiratory conditions (e.g., Emphysema, Cystic fibrosis) * Severe chronic gastrointestinal issues (e.g., bleeding ulcer, leaky gut syndrome) * Within 6 months of surgeries * Abnormal blood test results (e.g., potassium or magnesium outside normal range) * Impaired kidney or liver function * Refusal to taper off of selective serotonin reuptake inhibitor (SSRI) medication
Study Locations (1)
Axial Therapeutic Research
Northridge, California, United States